Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares
September 28 2022 - 12:08AM
Business Wire
Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the
development of NAM-enabled cell therapies for patients with
hematologic and solid cancers and other serious diseases, today
announced the pricing of a follow-on public offering of 12,905,000
of its ordinary shares at a public offering price of $1.55 per
share for aggregate gross proceeds of $20 million, before deducting
underwriting discounts and commissions and estimated offering
expenses. In addition, Gamida Cell has granted the underwriters a
30-day option to purchase up to an additional 1,935,750 ordinary
shares at the public offering price, less the underwriting
discounts and commissions. The offering is expected to close on or
about September 30, 2022, subject to satisfaction of customary
closing conditions.
Gamida Cell intends to use the net proceeds from this offering,
together with its existing cash and cash equivalents and trading
financial assets: for (i) commercial readiness activities to
support potential launch of omidubicel, if approved; (ii) the
continued clinical development of its NK product candidates,
including GDA-201; and (iii) general corporate purposes, including
general and administrative expenses and working capital.
Piper Sandler & Co. and JMP Securities, a Citizens Company,
are acting as joint book-running managers for this offering.
A registration statement on Form S-3 (File No. 333-259472)
relating to the ordinary shares has been filed with the Securities
and Exchange Commission and declared effective on April 1, 2022.
This offering will be made only by means of a prospectus
supplement. Copies of the final prospectus supplement and the
accompanying prospectus related to this offering may be obtained,
when available, from: Piper Sandler & Co., 800 Nicollet Mall,
J12S03, Minneapolis, Minnesota 55402, Attention: Prospectus
Department, by telephone at (800) 747-3924 or by email at
prospectus@psc.com,or JMP Securities LLC, 600 Montgomery Street,
Suite 1100, San Francisco, California 94111, Attention: Prospectus
Department, by calling (415) 835-8985, or by e-mail at
syndicate@jmpsecurities.com. Investors may also obtain these
documents at no cost by visiting the SEC’s website at
http://www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities, in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Gamida Cell
Gamida Cell is pioneering a diverse immunotherapy pipeline of
potentially curative cell therapy candidates for patients with
solid tumor and blood cancers and other serious blood diseases. We
apply a proprietary expansion platform leveraging the properties of
NAM to allogeneic cell sources including umbilical cord
blood-derived cells and NK cells to create therapy candidates with
potential to redefine standards of care. These include omidubicel,
an investigational product with potential as a life-saving
alternative for patients in need of bone marrow transplant, and a
line of modified and unmodified NAM-enabled NK cells targeted at
solid tumor and hematological malignancies.
Forward Looking Statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995, including with respect to the use of proceeds and timing and
consummation of the closing of the public offering. These
forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including those that are described
in the Risk Factors sections of the preliminary prospectus
supplement for such offering filed with the SEC on September 27,
2022, and the documents incorporated by reference therein,
including without limitation the Company’s Quarterly Report on Form
10-Q filed with the SEC on August 15, 2022, the accompanying
prospectus and other filings that Gamida Cell makes with the SEC
from time to time (which are available at http://www.sec.gov), any
of which could cause the events and circumstances discussed in such
forward-looking statements to not occur on the terms described or
at all. Prospective investors are cautioned not to place undue
reliance on such forward-looking statements, which speak only as of
the date hereof. Gamida Cell undertakes no obligation to update any
such forward-looking statements after the date hereof, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220927006162/en/
Investor: Courtney Turiano Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com 1-212-362-1200
Media Inquiries: Heather DiVecchia Director, IR and
Corporate Communications Heather@gamida-cell.com 1-617-892-9083
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Apr 2023 to Apr 2024